Moreover, mimicking the allosteric interaction of COMP–AT1a by overexpressing the peptidomimetic of EGF2 domain (53 amino acids) showed therapeutic potential for AAA treatment, suggesting that an allosteric antagonism of AT1a signaling may represent a potential new therapeutic strategy for the treatment of cardiovascular diseases, such as AAA. Here, COMP is linked to cardiovascular disorder.